Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies

A randomized, double-blind, placebo-controlled study

Michael Hedenus, Magnus Adriansson, Jesus San Miguel, Mark H H Kramer, Martin R. Schipperus, Eeva Juvonen, Kerry Taylor, Andrew Belch, Albert Altés, Giovanni Martinelli, David Watson, James Matcham, Gregory Rossi, Timothy J. Littlewood

Research output: Contribution to journalArticle

279 Citations (Scopus)

Abstract

This phase 3, randomized, double-blind, placebo-controlled study was designed to evaluate the efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Patients (n = 344) with lymphoma or myeloma received darbepoetin alfa 2.25 μg/kg or placebo s.c., once weekly for 12 weeks. The percentage of patients achieving a haemoglobin response was significantly higher in the darbepoetin alfa group (60%) than in the placebo group (18%) (P <0.001), regardless of baseline endogenous erythropoietin level. However, increased responsiveness was observed in patients with lower baseline erythropoietin levels. Darbepoetin alfa also resulted in higher mean changes in haemoglobin than placebo from baseline to the last value during the treatment phase (1.80 g/dl vs 0.19 g/dl) and after 12 weeks of treatment (2.66 g/dl vs 0.69 g/dl). A significantly lower percentage of patients in the darbepoetin alfa group received red blood cell transfusions than in the placebo group (P <0.001). The efficacy of darbepoetin alfa was consistent for patients with lymphoma or myeloma. Improvements in quality of life were also observed with darbepoetin alfa. The overall safety profile of darbepoetin alfa was consistent with that expected for this patient population. Darbepoetin alfa significantly increased haemoglobin and reduced red blood cell transfusions in patients with lymphoproliferative malignancies receiving chemotherapy.

Original languageEnglish
Pages (from-to)394-403
Number of pages10
JournalBritish Journal of Haematology
Volume122
Issue number3
DOIs
Publication statusPublished - Aug 2003

Fingerprint

Placebos
Safety
Neoplasms
Erythrocyte Transfusion
Hemoglobins
Erythropoietin
Lymphoma
Darbepoetin alfa
Quality of Life
Drug Therapy
Therapeutics
Population

Keywords

  • Anaemia
  • Cancer
  • Erythropoietin
  • Lymphoma
  • Myeloma

ASJC Scopus subject areas

  • Hematology

Cite this

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies : A randomized, double-blind, placebo-controlled study. / Hedenus, Michael; Adriansson, Magnus; San Miguel, Jesus; Kramer, Mark H H; Schipperus, Martin R.; Juvonen, Eeva; Taylor, Kerry; Belch, Andrew; Altés, Albert; Martinelli, Giovanni; Watson, David; Matcham, James; Rossi, Gregory; Littlewood, Timothy J.

In: British Journal of Haematology, Vol. 122, No. 3, 08.2003, p. 394-403.

Research output: Contribution to journalArticle

Hedenus, M, Adriansson, M, San Miguel, J, Kramer, MHH, Schipperus, MR, Juvonen, E, Taylor, K, Belch, A, Altés, A, Martinelli, G, Watson, D, Matcham, J, Rossi, G & Littlewood, TJ 2003, 'Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study', British Journal of Haematology, vol. 122, no. 3, pp. 394-403. https://doi.org/10.1046/j.1365-2141.2003.04448.x
Hedenus, Michael ; Adriansson, Magnus ; San Miguel, Jesus ; Kramer, Mark H H ; Schipperus, Martin R. ; Juvonen, Eeva ; Taylor, Kerry ; Belch, Andrew ; Altés, Albert ; Martinelli, Giovanni ; Watson, David ; Matcham, James ; Rossi, Gregory ; Littlewood, Timothy J. / Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies : A randomized, double-blind, placebo-controlled study. In: British Journal of Haematology. 2003 ; Vol. 122, No. 3. pp. 394-403.
@article{06d7f0fea4184232a135a3276fa0da43,
title = "Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study",
abstract = "This phase 3, randomized, double-blind, placebo-controlled study was designed to evaluate the efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Patients (n = 344) with lymphoma or myeloma received darbepoetin alfa 2.25 μg/kg or placebo s.c., once weekly for 12 weeks. The percentage of patients achieving a haemoglobin response was significantly higher in the darbepoetin alfa group (60{\%}) than in the placebo group (18{\%}) (P <0.001), regardless of baseline endogenous erythropoietin level. However, increased responsiveness was observed in patients with lower baseline erythropoietin levels. Darbepoetin alfa also resulted in higher mean changes in haemoglobin than placebo from baseline to the last value during the treatment phase (1.80 g/dl vs 0.19 g/dl) and after 12 weeks of treatment (2.66 g/dl vs 0.69 g/dl). A significantly lower percentage of patients in the darbepoetin alfa group received red blood cell transfusions than in the placebo group (P <0.001). The efficacy of darbepoetin alfa was consistent for patients with lymphoma or myeloma. Improvements in quality of life were also observed with darbepoetin alfa. The overall safety profile of darbepoetin alfa was consistent with that expected for this patient population. Darbepoetin alfa significantly increased haemoglobin and reduced red blood cell transfusions in patients with lymphoproliferative malignancies receiving chemotherapy.",
keywords = "Anaemia, Cancer, Erythropoietin, Lymphoma, Myeloma",
author = "Michael Hedenus and Magnus Adriansson and {San Miguel}, Jesus and Kramer, {Mark H H} and Schipperus, {Martin R.} and Eeva Juvonen and Kerry Taylor and Andrew Belch and Albert Alt{\'e}s and Giovanni Martinelli and David Watson and James Matcham and Gregory Rossi and Littlewood, {Timothy J.}",
year = "2003",
month = "8",
doi = "10.1046/j.1365-2141.2003.04448.x",
language = "English",
volume = "122",
pages = "394--403",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "3",

}

TY - JOUR

T1 - Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies

T2 - A randomized, double-blind, placebo-controlled study

AU - Hedenus, Michael

AU - Adriansson, Magnus

AU - San Miguel, Jesus

AU - Kramer, Mark H H

AU - Schipperus, Martin R.

AU - Juvonen, Eeva

AU - Taylor, Kerry

AU - Belch, Andrew

AU - Altés, Albert

AU - Martinelli, Giovanni

AU - Watson, David

AU - Matcham, James

AU - Rossi, Gregory

AU - Littlewood, Timothy J.

PY - 2003/8

Y1 - 2003/8

N2 - This phase 3, randomized, double-blind, placebo-controlled study was designed to evaluate the efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Patients (n = 344) with lymphoma or myeloma received darbepoetin alfa 2.25 μg/kg or placebo s.c., once weekly for 12 weeks. The percentage of patients achieving a haemoglobin response was significantly higher in the darbepoetin alfa group (60%) than in the placebo group (18%) (P <0.001), regardless of baseline endogenous erythropoietin level. However, increased responsiveness was observed in patients with lower baseline erythropoietin levels. Darbepoetin alfa also resulted in higher mean changes in haemoglobin than placebo from baseline to the last value during the treatment phase (1.80 g/dl vs 0.19 g/dl) and after 12 weeks of treatment (2.66 g/dl vs 0.69 g/dl). A significantly lower percentage of patients in the darbepoetin alfa group received red blood cell transfusions than in the placebo group (P <0.001). The efficacy of darbepoetin alfa was consistent for patients with lymphoma or myeloma. Improvements in quality of life were also observed with darbepoetin alfa. The overall safety profile of darbepoetin alfa was consistent with that expected for this patient population. Darbepoetin alfa significantly increased haemoglobin and reduced red blood cell transfusions in patients with lymphoproliferative malignancies receiving chemotherapy.

AB - This phase 3, randomized, double-blind, placebo-controlled study was designed to evaluate the efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Patients (n = 344) with lymphoma or myeloma received darbepoetin alfa 2.25 μg/kg or placebo s.c., once weekly for 12 weeks. The percentage of patients achieving a haemoglobin response was significantly higher in the darbepoetin alfa group (60%) than in the placebo group (18%) (P <0.001), regardless of baseline endogenous erythropoietin level. However, increased responsiveness was observed in patients with lower baseline erythropoietin levels. Darbepoetin alfa also resulted in higher mean changes in haemoglobin than placebo from baseline to the last value during the treatment phase (1.80 g/dl vs 0.19 g/dl) and after 12 weeks of treatment (2.66 g/dl vs 0.69 g/dl). A significantly lower percentage of patients in the darbepoetin alfa group received red blood cell transfusions than in the placebo group (P <0.001). The efficacy of darbepoetin alfa was consistent for patients with lymphoma or myeloma. Improvements in quality of life were also observed with darbepoetin alfa. The overall safety profile of darbepoetin alfa was consistent with that expected for this patient population. Darbepoetin alfa significantly increased haemoglobin and reduced red blood cell transfusions in patients with lymphoproliferative malignancies receiving chemotherapy.

KW - Anaemia

KW - Cancer

KW - Erythropoietin

KW - Lymphoma

KW - Myeloma

UR - http://www.scopus.com/inward/record.url?scp=0041627742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041627742&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2003.04448.x

DO - 10.1046/j.1365-2141.2003.04448.x

M3 - Article

VL - 122

SP - 394

EP - 403

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -